Skip to content
Wednesday 12 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,840.14
-0.04%
DAX
26,490.68
+0.38%
CAC 40
8,694.93
-0.23%
STOXX 50
6,559.69
+0.13%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

health

  • Sales downturn at Spectris after sale of software firm

    May 2, 2024

    Precision instrument maker Spectris experienced a slower first start to the year than expected, it announced in its quarterly update.

  • Haleon posts healthy first quarter update after UK job cuts

    May 1, 2024

    Revenue at Haleon was up in the first quarter despite its announcement yesterday that it would cut over 400 jobs in the UK, as the consumer healthcare firm posted a quarterly update in line with expectations.

  • UK firms want tax incentives to invest in employee health amid growing sickness crisis

    April 30, 2024

    The report comes amid a growing debate about the impact of long-term sickness on the UK labour force.

  • Astrazeneca: London-listed pharma giant heralds successful breast cancer drug

    April 29, 2024

    Astrazeneca has found that Enhertu helped patients live longer without their breast cancer getting worse compared to standard chemotherapy.

  • One Health Group sees patients soar as NHS buckles with growing waiting lists

    April 29, 2024

    One Health's services are easing the load on the nation's embattled health service which is buckling under the weight of long waiting lists.

  • Drugmaker Indivior seeks shareholder approval to move primary listing from London to New York

    April 25, 2024

    Opioid dependence treatment maker Indivior has confirmed a plan to move its primary stock market listing from London to New York this summer in yet another blow to the capital's beleaguered bourse.

  • Record revenue at former BBC Dragons’ Den star Duncan Bannatyne’s health and hotels group

    April 25, 2024

    The health club and hotels group owned by former BBC Dragons' Den investor Duncan Bannatyne has a record revenue and its highest profit since before the pandemic.

  • Is your online therapist exploiting you? Are they even qualified?

    April 25, 2024

    A combination of unlicensed therapists and the rise of therapy culture has led to the wild west of Betterhelp, writes Lucy Kenningham

  • ‘Moral mission’: Sunak to reform benefits system in fight against long-term sickness

    April 19, 2024

    Rishi Sunak has announced plans to reform Britain’s disability benefits system in what he called a “moral mission” to address the rise in long-term sickness.

  • Rishi Sunak wants to end ‘sick note culture’ and get Britain back to work 

    April 19, 2024

    Rishi Sunak wants to end the “sick note culture” and get Britain back to work, in a major speech on welfare reform.

Posts pagination

  • Previous
  • Page 1
  • …
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • …
  • Page 37
  • Next

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Hargreaves Lansdown orders staff back to office

  • As it happened: Intel, Arm shares slide; Oil climbs higher

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook